Venetoclax Production Approval

Release date: 2024-07-10 15:10:31     Article From: Lucius Laos     Recommended: 193

09L1009_23 维奈托克 批文_00.jpg

Venetoclax is a BCL-2 inhibitor used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as well as acute myeloid leukemia (AML). Venetoclax selectively inhibits the anti apoptotic protein BCL-2, which is overexpressed in chronic lymphocytic leukemia (CLL) cells and acute myeloid leukemia (AML) cells. BCL-2 mediates tumor cell survival and is associated with chemotherapy resistance. Venetoclax directly binds to BCL-2 protein, replacing pro apoptotic proteins and restoring the apoptotic process.

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Contact US

Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

Whatsapp:

ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved

whatsapp